|
KMID : 0371619950110010107
|
|
Journal of Wonkwang Medical Science
1995 Volume.11 No. 1 p.107 ~ p.114
|
|
|
Clinical Efficacy of Combination Therapy of Sulphonylurea and Acarbose in Patients with NIDDM
|
|
|
|
|
Abstract
|
|
|
The alpha glucosidase inhibitor. Acarbose (Glucobay(r), Bayer) inhibits carbohydrate digestion and suppresser or delays absorption of the final breakdown products, glucose and fructose when it is taken orally with meal. Therefore, clinical
usefulness of
acarbose is anticipated in NIDDM patients treated simultaneously by a sulfonylurea compound and acarbose.
In the current study its ability to lower plasma glucose levels was studied in 12 placebo-treated NIDDM patients and in 12 patients with NIDDM, poorly controlled on diet plus sulfonylurea drugs. Patients were studied before and 16 weeks after the
addition of acarbose to their treatment program, and there as a notable fall in fasting and postprandial plasma glucose concentrations. In addition to the improvement in glycemia, acarbose treatment also led to a notable reduction in Hb A1c
levels.
The
adverse effects during administration of acarbose was negligible. Only one patient complained of mild abdominal bloating.
These data suggest that acarbose may be a useful additional method in the treatment of patients with NIDDM.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|